Suppr超能文献

鉴定一种靶向 UHM 结构域的小分子剪接抑制剂。

Identification of a small molecule splicing inhibitor targeting UHM domains.

机构信息

SABNP, Univ Evry, INSERM U1204, Université Paris-Saclay, Evry, France.

SYNSIGHT, Genopole Entreprises, Evry, France.

出版信息

FEBS J. 2022 Feb;289(3):682-698. doi: 10.1111/febs.16199. Epub 2021 Oct 4.

Abstract

Splicing factor mutations are frequent in myeloid neoplasms, blood cancers, and solid tumors. Cancer cells harboring these mutations present a particular vulnerability to drugs that target splicing factors such as SF3b155 or CAPERα. Still, the arsenal of chemical probes that target the spliceosome is very limited. U2AF homology motifs (UHMs) are common protein interaction domains among splicing factors. They present a hydrophobic pocket ideally suited to anchor small molecules with the aim to inhibit protein-protein interaction. Here, we combined a virtual screening of a small molecules database and an in vitro competition assay and identified a small molecule, we named UHMCP1 that prevents the SF3b155/U2AF interaction. NMR analyses and molecular dynamics simulations confirmed the binding of this molecule in the hydrophobic pocket of the U2AF UHM domain. We further provide evidence that UHMCP1 impacts RNA splicing and cell viability and is therefore an interesting novel compound targeting an UHM domain with potential anticancer properties.

摘要

剪接因子突变在髓系肿瘤、血液癌症和实体肿瘤中很常见。携带这些突变的癌细胞对靶向剪接因子(如 SF3b155 或 CAPERα)的药物特别敏感。然而,靶向剪接体的化学探针库非常有限。U2AF 同源基序 (UHM) 是剪接因子中常见的蛋白质相互作用结构域。它们形成一个疏水性口袋,非常适合锚定小分子,从而抑制蛋白质-蛋白质相互作用。在这里,我们结合了小分子数据库的虚拟筛选和体外竞争测定,鉴定出一种小分子,我们将其命名为 UHMCP1,它可以阻止 SF3b155/U2AF 的相互作用。NMR 分析和分子动力学模拟证实了该分子在 U2AF UHM 结构域的疏水性口袋中的结合。我们进一步提供了证据表明 UHMCP1 影响 RNA 剪接和细胞活力,因此是一种具有潜在抗癌特性的靶向 UHM 结构域的新型化合物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验